{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"NCT05445908","nct_id":"NCT05445908","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05445908. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants received SKB264 followed by KL-A167","label":"SKB264+KL-A167（Part1，TNBC）","type":"EXPERIMENTAL"},{"description":"Participants received SKB264","label":"SKB264（Part2，TNBC）","type":"EXPERIMENTAL"},{"description":"Participants received SKB264 followed by KL-A167","label":"SKB264+KL-A167（Part2，TNBC）","type":"EXPERIMENTAL"},{"description":"Participants received SKB264","label":"SKB264（Part3，HR+/HER2- BC）","type":"EXPERIMENTAL"},{"description":"Participants received SKB264 followed by KL-A167","label":"SKB264+KL-A167（Part3，HR+/HER2- BC）","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-07-31","type":"ACTUAL"},"conditions":["Triple-negative Breast Cancer and HR+/HER2- BC"],"enrollment":{"count":184,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"SKB264","otherNames":[],"type":"DRUG"},{"name":"KL-A167","otherNames":[],"type":"DRUG"}],"last_update":"2026-08-28","lead_sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","official_title":"A Phase 2 Clinical Study of SKB264 With/Without KL-A167 in Patients With Unresectable Locally Advanced, Recurrent or Metastatic HER2-negative Breast Cancer Who Have Not Received Prior Systemic Therapy","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2026-07-31","type":"ACTUAL"},"primary_outcomes":[{"measure":"Incidence and severity of adverse events (AEs)","timeFrame":"From baseline up to 30 days after last dose or to the beginning of the new anti-cancer therapy, up to 24 months"},{"measure":"Objective Response Rate (ORR)","timeFrame":"From baseline to first documented objective response, up to 24 months"}],"references":[],"start_date":{"date":"2022-08-17","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer","url":"https://clinicaltrials.gov/study/NCT05445908"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05445908"}